vit-2763
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2020 (NCT04364269)
Timeline
Indications
Mechanism of action
- HepcidinSupplementation
HAMP supplementation
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NCc1ncccc1F)c1coc(CCNCCc2nc3ccccc3[nH]2)n1- Mol. weight
- 408.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4596566 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06996184 | Phase 1 | May 27, 2025 | CSL Behring |
| NCT05077436 | Phase 1 | Oct 14, 2021 | Vifor Inc. |
| NCT04938635 | Phase 2 | Sep 20, 2021 | Covance, Vifor Inc. |
| NCT04817670 | Phase 2 | Jun 9, 2021 | Covance, Vifor Inc. |
| NCT04364269 | Phase 2 | Jun 30, 2020 | Covance, Vifor Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vifor Inc. | For profit | 4 | 4 | 2 | 2020 |
| Covance | For profit | 3 | 0 | 1 | 2020 |
| CSL Behring | For profit | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1